Exact Sciences(EXAS)

MADISON, WIDiagnostics2 H-1B visas (FY2023)

Focus: Exact Sciences is a public diagnostics company headquartered in Madison, WI with 5,001-10,000 employees, focused on cancer screening and detection through molecular testing platforms. The company generates $2.5B in annual revenue (FY 2025) and operates as a scaled player in the precision diagnostics market.

Profile data last refreshed 14h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

5001-10000

Open Jobs

About Exact Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Exact Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

37 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$2.5B

Key Products

Cologuard

Colorectal Cancer Screening

Peak

Flagship non-invasive stool DNA screening test driving majority of commercial revenue and market adoption in CRC screening.

Pipeline & Clinical Trials

Help build intelligence for Exact Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established $2.5B revenue base with 19% YoY growth (FY2024-2025) signals stability and resources for career development.
Leading position in high-growth cancer screening market with Cologuard as flagship product driving recurring diagnostic revenue streams.
17% R&D intensity ($427M in FY2025) demonstrates commitment to innovation across early detection and minimal residual disease applications.

Watch Out For

Consecutive annual net losses (-$204M FY2025, -$623M FY2024) raise questions about path to profitability despite revenue growth.
Pipeline consists entirely of collection methods, screening protocols, and assay development with no traditional clinical trials, limiting exposure to drug development career trajectories.

Generated by Claude from Exact Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Cologuard

Colorectal Cancer

N/A

Cologuard

Colon Cancer

N/A

Blood Sample Collection

Hepatocellular Carcinoma

N/A

mt-sDNA screening test

Colorectal Cancer

N/A